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Background
The NNRTI etravirine (ETR; TMC125) has demonstrated
durable antiviral activity and favourable tolerability in
treatment-experienced patients in the Phase III DUET tri-
als. We report week 48 virological response in the sub-
group of patients who were fully sensitive to ETR,
analysed according to enfuvirtide (ENF) use and number
of active background agents.
Methods
HIV-1-infected, treatment-experienced patients with doc-
umented NNRTI-resistance, ≥3 primary PI mutations and
viral load (VL) >5000 copies/mL were randomised 1:1 to
receive ETR 200 mg BID or placebo following a meal plus
a background regimen (BR) of darunavir/ritonavir,
NRTI(s) and optional ENF. The current analysis included
all patients who were fully sensitive to ETR. Phenotypic
Sensitivity Score (PSS; Antivirogram®) was used to deter-
mine the number of active background agents; ETR was
considered active if the fold change in EC50 (FC) was ≤3;
darunavir if FC ≤10; NRTIs if FC was < cut-off defined on
Antivirogram® and ENF if used de novo. The pooled anal-
ysis was pre-specified.
Summary of Results
In total, 599 and 604 patients received ETR + BR and pla-
cebo + BR, respectively. Baseline demographics and char-
acteristics were similar between treatment groups, with a
median VL of 4.8 log10 copies/mL in both treatment
groups and CD4 cell counts of 99 vs. 109 cells/mm3 in the
ETR group and placebo groups, respectively. After 48
weeks of treatment, 61% of patients receiving ETR + BR in
the overall population achieved a confirmed virological
response (<50 copies/mL) vs. 40% in the placebo group
(p < 0.0001). Virological response by PSS (0, 1 and ≥2
active antiretrovirals [ARVs]) in patients fully sensitive to
ETR according to ENF use (de novo or not de novo) is pre-
sented in the table in Figure 1. In the overall and the ENF
not de-novo subgroups, virological response increased
with increasing number of active agents in the BR. The dif-
ference between the treatment groups was most apparent
in patients who had no active background agents.
Conclusion
In patients with virus fully sensitive to ETR, the virological
response was higher in the ETR + BR group than in the pla-
cebo + BR group, irrespective of ENF use or number of
active background agents. These results complement cur-
rent guidelines, which recommend a minimum of two
active agents in any treatment regimen.
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